Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Burtness

Showing results (131-140 of 184) with videos related to

Pageof 19
Sort By:
Annals of Surgical Oncology|August 21, 2010
Defining venous involvement in borderline resectable pancreatic cancerYun Shin Chun, Barton N Milestone, James C Watson, et al.
Oral Oncology|March 28, 2024
An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancersVasiliki Xirou, Myrto Moutafi, Yalai Bai, et al.
JNCI Cancer Spectrum|January 22, 2026
STING predicts patterns of failure in locally advanced head and neck squamous cell carcinomaTyler MacNeil, Thomas J Hayman, Shengguo Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2019
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck CancerAthanassios Argiris, Shuli Li, Panayiotis Savvides, et al.
Lancet (London, England)|December 5, 2018
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E W Cohen, Denis Soulières, Christophe Le Tourneau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2019
Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical OpinionDavid J Adelstein, Nofisat Ismaila, Jamie A Ku, et al.
AJNR. American Journal of Neuroradiology|May 16, 2025
FDG-PET intensity normalization improves radiomics- based survival prediction in oropharyngeal cancer patients: a comparison of the SUV with alternative normalization techniquesSeyedmehdi Payabvash, Kariem Sharaf, Tal Zeevi, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
AURKA inhibition amplifies DNA replication stress to foster WEE1 kinase dependency and synergistic antitumor effects with WEE1 inhibition in cancersJong Woo Lee, Jackie Shi, Julian Barrantes, et al.
The Lancet. Oncology|May 10, 2016
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialKei Muro, Hyun Cheol Chung, Veena Shankaran, et al.
Small (Weinheim an Der Bergstrasse, Germany)|February 20, 2024
Multiplexable and Scalable Aqueous Synthesis Platform for Oleate-Based, Bilayer-Coated Gold NanoparticlesAndreas Backhaus, Jillian Albrecht, Gaukhar Alzhanova, et al.
Pageof 19

Showing results (131-140 of 184) with videos related to

Sort By:
Pageof 19
Annals of Surgical Oncology|August 21, 2010
Defining venous involvement in borderline resectable pancreatic cancerYun Shin Chun, Barton N Milestone, James C Watson, et al.
Oral Oncology|March 28, 2024
An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancersVasiliki Xirou, Myrto Moutafi, Yalai Bai, et al.
JNCI Cancer Spectrum|January 22, 2026
STING predicts patterns of failure in locally advanced head and neck squamous cell carcinomaTyler MacNeil, Thomas J Hayman, Shengguo Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2019
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck CancerAthanassios Argiris, Shuli Li, Panayiotis Savvides, et al.
Lancet (London, England)|December 5, 2018
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E W Cohen, Denis Soulières, Christophe Le Tourneau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2019
Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical OpinionDavid J Adelstein, Nofisat Ismaila, Jamie A Ku, et al.
AJNR. American Journal of Neuroradiology|May 16, 2025
FDG-PET intensity normalization improves radiomics- based survival prediction in oropharyngeal cancer patients: a comparison of the SUV with alternative normalization techniquesSeyedmehdi Payabvash, Kariem Sharaf, Tal Zeevi, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
AURKA inhibition amplifies DNA replication stress to foster WEE1 kinase dependency and synergistic antitumor effects with WEE1 inhibition in cancersJong Woo Lee, Jackie Shi, Julian Barrantes, et al.
The Lancet. Oncology|May 10, 2016
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialKei Muro, Hyun Cheol Chung, Veena Shankaran, et al.
Small (Weinheim an Der Bergstrasse, Germany)|February 20, 2024
Multiplexable and Scalable Aqueous Synthesis Platform for Oleate-Based, Bilayer-Coated Gold NanoparticlesAndreas Backhaus, Jillian Albrecht, Gaukhar Alzhanova, et al.
Pageof 19